| Segment | Q2 '24 | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 | Q1 '26 |
|---|---|---|---|---|---|---|---|---|
| HIV | $18.94M | $18.35M | $15.43M | $12.9M | $14.4M | $11.14M | $11.36M | $13.02M |
| Sample Management Solutions | $13.65M | $12.81M | $14.81M | $9.11M | $9.86M | $10.31M | $9.09M | $9.06M |
| HCV | $12.61M | $3.23M | — | $4.33M | $4.13M | $2.6M | — | $2.66M |
| Other Product And Services Revenues | $2.31M | $1.2M | $42.55M | $773K | $994K | $1.2M | — | $1.62M |
| Non-product and services revenues | $386K | $263K | $214K | $934K | $1.4M | $1.75M | $1.89M | $1.55M |
| COVID-19 | $810K | $2.16M | $10.19M | $461K | $28K | $89K | $13.18M | $18K |
| Risk Assessment Testing | $4.73M | $1.91M | $2.09M | $1.42M | $446K | $0 | $0 | $0 |
| Total | $54.34M | $39.92M | $37.45M | $29.93M | $31.24M | $27.09M | $26.76M | $27.93M |